Novo Nordisk A/S Sponsored ADR Class B (NVO.US) jumped in pre-market trading, Ozempic has better cardiovascular protective effects than traditional drugs like Lantus.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) saw its largest one-day increase in a month, as its diabetes blockbuster drug Ozempic outperformed Eli Lilly's older drug Trulicity in a real-world study of some patients in the United States. At the European Association for the Study of Diabetes (EAD) meeting in Vienna, Novo Nordisk A/S Sponsored ADR Class B reported that patients with medical insurance who took Ozempic had a 23% lower risk of heart attack, stroke, or death compared to patients taking Trulicity. This study followed nearly 60,000 diabetes and heart disease patients. Both Ozempic and Trulicity belong to the GLP-1 class of drugs, which have revolutionized obesity treatment. The concept of "some drugs being more effective in preventing heart disease than others" is the cornerstone of Novo Nordisk A/S Sponsored ADR Class B's competition with Eli Lilly in the competitive field of obesity and related diseases. Eli Lilly has been gaining market share with its new drugs Mounjaro and Zepbound. The stock price of Novo Nordisk A/S Sponsored ADR Class B rose 6.5% in Copenhagen at one point. Another head-to-head study was also presented at the Thursday meeting, which found that Mounjaro was roughly comparable to Trulicity in reducing the risk of heart attack, stroke, and death. However, these two studies are not directly comparable as one was a randomized trial and the other was an observational study. Before the Thursday US stock market opened, Novo Nordisk A/S Sponsored ADR Class B was up 6.01% at $61.70.